| Name | Title | Contact Details |
|---|---|---|
Mark Plavsic |
Chief Technology Officer | Profile |
Neuron23™ Inc. is an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases.
ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies.
HiFiBiO SAS commercializes proprietary single cell technologies for applications in drug and biomarker discovery and development.
Tri-Source Pharma is a pharmaceutical manufacturer/distributor operating in both the human and animal health care industries.
Kyn Therapeutics is building a new generation of immuno-oncology therapies targeting powerful immunosuppressive metabolic networks. We envision a future where immunotherapies are the foundation of every cancer patient`s treatment, delivering rapid and durable responses. The Kyn team is composed of drug hunters, translational researchers and entrepreneurs drawn from many of the largest innovators in biotechnology supported by world-class advisors, and is backed by a seasoned board of directors anchored by OrbiMed Healthcare Fund Management and Atlas Venture. Kyn Therapeutics is headquartered in the biotech hub of Cambridge, Massachusetts.